Vasiliki Danilatou

Dr. Vasiliki Danilatou

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VDVasiliki Danilatou
Vasiliki Danilatou
SNStylianos Nikolakakis
Stylianos Nikolakakis
DADespoina Antonakaki
Despoina Antonakaki
CTChristos Tzagkarakis
Christos Tzagkarakis
DMDimitrios Mavroidis
Dimitrios Mavroidis
Sotiris IoannidisSotiris Ioannidis
Sotiris Ioannidis
Intensive care unit (ICU) patients with venous thromboembolism (VTE) and/or cancer suffer from high mortality rates. Mortality prediction in the ICU has been a major medical challenge for which several scoring systems exist but lack in specificity. This study focuses on two target groups, namely patients with thrombosis or cancer. The main goal is to develop and validate interpretable machine learning (ML) models to predict early and late mortality, while exploiting all available data stored in the medical record. To this end, retrospective data from two freely accessible databases, MIMIC-III and eICU, were used. Well-established ML algorithms were implemented utilizing automated and purposely built ML frameworks for addressing class imbalance. Prediction of early mortality showed excellent performance in both disease categories, in terms of the area under the receiver operating characteristic curve (AUC–ROC): VTE-MIMIC-III 0.93, eICU 0.87, cancer-MIMIC-III 0.94. On the other hand, late mortality prediction showed lower performance, i.e., AUC–ROC: VTE 0.82, cancer 0.74–0.88. The predictive model of early mortality developed from 1651 VTE patients (MIMIC-III) ended up with a signature of 35 features and was externally validated in 2659 patients from the eICU dataset. Our model outperformed traditional scoring systems in predicting early as well as late mortality. Novel biomarkers, such as red cell distribution width, were identified.

4 April 2024 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
VDVasiliki Danilatou
Vasiliki Danilatou
Dimitris DimopoulosDimitris Dimopoulos
Dimitris Dimopoulos
TKTheodoros Kostoulas
Theodoros Kostoulas
JDJames Douketis
James Douketis
Background Venous thromboembolism (VTE) is a chronic disorder with a significant health and economic burden. Several VTE-specific clinical prediction models (CPMs) have been used to assist physicians in decision-making but have several limitations. This systematic review explores if machine learning (ML) can enhance CPMs by analyzing extensive patient data derived from electronic health records. We aimed to explore ML-CPMs' applications in VTE for risk stratification, outcome prediction, diagnosis, and treatment. Methods Three databases were searched: PubMed, Google Scholar, and IEEE electronic library. Inclusion criteria focused on studies using structured data, excluding non-English publications, studies on non-humans, and certain data types such as natural language processing and image processing. Studies involving pregnant women, cancer patients, and children were also excluded. After excluding irrelevant studies, a total of 77 studies were included. Results Most studies report that ML-CPMs outperformed traditional CPMs in terms of receiver operating area under the curve in the four clinical domains that were explored. However, the majority of the studies were retrospective, monocentric, and lacked detailed model architecture description and external validation, which are essential for quality audit. This review identified research gaps and highlighted challenges related to standardized reporting, reproducibility, and model comparison. Conclusion ML-CPMs show promise in improving risk assessment and individualized treatment recommendations in VTE. Apparently, there is an urgent need for standardized reporting and methodology for ML models, external validation, prospective and real-world data studies, as well as interventional studies to evaluate the impact of artificial intelligence in VTE.

1 April 2005 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ESEftichia Stiakaki
Eftichia Stiakaki
Ioannis GermanakisIoannis Germanakis
Ioannis Germanakis
CSCaterina Sfyridaki
Caterina Sfyridaki
NKNikos Katzilakis
Nikos Katzilakis
VDVasiliki Danilatou
Vasiliki Danilatou
MKMaria Kalmanti
Maria Kalmanti

24 July 2021 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
DDDimitris Dimopoulos
Dimitris Dimopoulos
AZAndreas Zacharioudakis
Andreas Zacharioudakis
GKGeorgios Kazamias
Georgios Kazamias
VDVasiliki Danilatou
Vasiliki Danilatou
DKDimitra Katerini
Dimitra Katerini
PKPavlos Koutentakis
Pavlos Koutentakis
Ligneous conjunctivitis is a rare form of chronic, recurrent conjunctivitis characterized by wood-like, fibrinous pseudomembranes, which may be associated with systemic disease manifestations. It has been associated with congenital plasminogen (PLG) deficiency that is inherited with an autosomal recessive pattern due to mutations in the PLG gene and a variety of other genes, leading to disturbed wound healing. In this case report, we present the clinical, laboratory, and histopathological findings of a 36-year-old female patient who presented at the ophthalmology department with complaints of redness, irritation for the previous few weeks, and appearance of membranous lesions mainly on the tarsal conjunctivae. During biomicroscopic examination we found thick, yellowish-white pseudomembranes, and conjunctival proliferation with ligneous induration on the conjunctiva, located on the upper eyelids. Histopathological evaluations showed up ligneous conjunctivitis and laboratory evaluation confirmed a severe plasminogen deficiency (PLG < 2%). The patient was treated with topical fresh frozen plasma (FFP), topical steroids, heparin eye drops, and artificial tear drops daily, without systemic therapy.

1 September 2012 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
MKMaria Kaparou
Maria Kaparou
VDVasiliki Danilatou
Vasiliki Danilatou
ELEvagelia Lydaki
Evagelia Lydaki
GSGeorge Stathoudakis
George Stathoudakis
IBIrini Bolonaki
Irini Bolonaki
KFKalliopi Foundouli
Kalliopi Foundouli

1 November 2022
Verified
Conference Paper
Closed access
PSPanagiotis Symeonidis
Panagiotis Symeonidis
TKTheodoros Kostoulas
Theodoros Kostoulas
VDVasiliki Danilatou
Vasiliki Danilatou
CAChristos Andras
Christos Andras
SCStergios Chairistanidis
Stergios Chairistanidis
Drug recommendation is denoted as the task of predicting drug combinations for patients' therapies with complex diseases (i.e., thrombosis, diabetes, etc.). These patients usually suffer from polypharmacy, and consequently various drug drug interactions. In this paper, we integrate the patients' Electronic Health Records (EHRs) with an adversarial Drug-Drug Interaction (DDI) knowledge graph to predict the next drug combination for a patient's therapy and minimize the drug side effects. In particular, we integrate an EHR graph, which incorporates the patient, the disease, the therapy, and the drug information, with an Adversarial DDI knowledge graph to recommend both accurate and safe medication. We also predict mortality and the time to death of critically-ill patients, to identify clinically meaningful predictors (e.g., harmful drug combinations). By identifying those drugs which can act adversarially, we are able to improve either the efficacy of the patient's therapy or minimize the toxicity and drug side effects. We have run experiments with a real-life medical data set. Our results show that we can assist doctors to prescribe effective and safe medication for the patients' treatment.